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Alzheimer's dementia (AD) is characterized by a progressive memory loss, that leads to
profound emotional disturbances in later stages. The disease is accompanied by dysfunctions
within the system of cholinergic neurotransmission in the central
nervous system. The nerve impuls in cholinergic synapses is terminated
by the enzyme acetylcholinesterase (AChE), which cleaves the
neurotransmitter acetylcholine. Reversible inhibition of this enzyme
leads to an increase of the neurotransmitter concentration within the
synaptic cleft, which positively affects patients suffering from AD.
Based on the cholinergic hypothesis, this treatment solely has lead to drugs for the symptomatic
treatment of AD.
Being a potent inhibitor of AChE with an acceptable pharmacological and toxicological profile,
the amaryllidaceae alkaloid (–)-galanthamine is a promising lead structure for the development
of the next generation AD drugs.
In the course of this dissertation a new synthetic strategy for galanthamine was developed, which
is based on a stereoselective Heck reaction as the key step. The approach lead to the tetracyclic
framework of the galanthamine moiety. The new pathway was found to be a versatile tool for the
synthesis of derivatives of the lead structure galanthamine.
In accompanying Molecular Modelling studies the interactions between the enzyme and each
member of a database of known galanthamine derivatives was investigated by automated
docking. The employed techniques allowed for the correct prediction of the structure of the
galanthamine/AChE complex (species: Torpedo californica). Based on the docking results a 3D-
QSAR model was developed and successfully validated by different statistical methods. This
model is a useful tool to estimate the biological activities of new galanthamine deivatives.
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